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Background: Low bone mineral density (BMD) may constitute an underestimated
comorbidity in schizophrenia patients undergoing long-term antipsychotic treatment.
Glucagon-like peptide 1 (GLP-1) receptor agonists are antidiabetic drugs, which may
also affect bone turnover.
Methods: In planned secondary analyses of a 3 months, double-blind, randomized,
placebo-controlled trial (n = 45), we explored effects of the GLP-1 receptor agonist
exenatide 2mg once-weekly (n = 23), or placebo (n = 22) on bone turnover markers
(BTMs) and BMD in chronic, obese, antipsychotic-treated patients with schizophrenia
spectrum disorder. Baseline BTMs were compared to sex- and age-adjusted reference
values from a Danish population cohort, and T- and Z-scores were calculated for BMD.
Results: In women (n = 24), all baseline BTM measurements of procollagen type I
N-terminal propeptide (PINP) and C-terminal cross-linking telopeptide of type I collagen
(CTX) were within reference values. In men (n = 21), 5% displayed lower PINP and 14%
displayed lower CTX. One patient displayed BMD Z-score < −2, and 23% of patients
(17% of women and 29% of men) displayed −2.5< T-scores <–1 indicating osteopenia,
but none had osteoporosis. After treatment, PINP decreased at trend level significance
(P = 0.05), and body mass index BMD increased for L2–L4 (P = 0.016). No changes in
bone markers were significant after correction for mean prolactin levels.
Eriksson et al. Bone Status, Exenatide, and Schizophrenia
Conclusions: Sex- and age-adjusted measures of bone status in chronic, obese,
antipsychotic-treated patients appeared comparable to the reference population. Subtle
changes in bone markers during 3 months exenatide treatment may suggest beneficial
effects of GLP-1 receptor agonists on bone status in antipsychotic-treated patients, and
further studies should consider the potential influence of prolactin.
Keywords: exenatide, procollagen type I N-terminal propeptide (PINP), C-terminal cross-linking telopeptide of type
I collagen (CTX), bone mineral density, randomized controlled trial
INTRODUCTION
Antipsychotic medication is the mainstay of treatment of
schizophrenia and other psychotic disorders (1). The drug class
is generally effective in treating psychotic symptoms, however
around 30% of schizophrenia patients do not respond sufficiently
(2). Antipsychotics are widely associated with undesirable effects
such as extrapyramidal symptoms and dysmetabolism (3, 4), but
more recently, osteoporosis and increased risk of bone fractures
have also been linked to antipsychotic treatment (3).
Although studies have not consistently reported associations
between bone mineral density (BMD) and prolactin levels
in antipsychotic-treated patients (5), antipsychotic-induced
hyperprolactinaemia has been suggested a causal factor
underlying osteoporosis (6). BMD is commonly assessed by dual-
energy X-ray absorptiometry (DXA). According toWHO criteria
T-scores are used as thresholds for osteopenia and osteoporosis.
Osteopenia is defined as 1 to 2.5 standard deviations (SD) or
more below the average value for young healthy subjects of the
same sex (−1> T-score >−2.5), and osteoporosis is defined
as a T-score below −2.5 (T-score ≤−2.5) (7). Besides T-scores,
DXA enables calculation of a Z-score, which is a comparison
of bone density with a healthy population of the same age and
same sex. The reference range for Z-scores is ±2. In addition
to BMD measurements of bone mass, circulating bone turnover
markers (BTMs) can be used to evaluate changes in bone
formation and resorption. International consensus guidelines
recommend assessment of two BTMs: procollagen type I N-
terminal propeptide (PINP) (produced by osteoblasts during
bone formation), and C-terminal cross-linking telopeptide of
type I collagen (CTX) (released by osteoclasts during bone
resorption) (8, 9).
Glucagon-like peptide 1 (GLP-1) receptor agonists are known
to induce positive effects on metabolism (10), but the drugs
might also affect bone turnover. Animal models have indicated
positive effects of the GLP-1 receptor agonists exendin-4 and
liraglutide on bone metabolism (11–13). These findings have
motivated translational efforts aiming to investigate the potential
benefits of GLP-1 receptor agonists on bone status in humans.
Treatment with liraglutide has been shown to increase bone
formation in body weight-reduced obese women when compared
to placebo (14). Conversely, studies of type 2 diabetes patients
have indicated that GLP-1 receptor agonists have no effect on
bone metabolism or fracture risk (15, 16).
The current study comprises planned secondary analyses of
the “TAO study”: Treatment of antipsychotic-associated obesity
with a GLP-1 receptor agonist (17–20). The TAO study was
an investigator-initiated, double-blind, randomized, placebo-
controlled trial, investigating the effects of 3 months treatment
with the GLP-1 receptor agonist exenatide 2mg once-weekly in
chronic obese, antipsychotic-treated patients with schizophrenia
spectrum disorder. First we compared baseline BTMs with the
Danish Health 2006 study cohort as reference population (21),
and we calculated BMD T- and Z-scores. Next, we compared
baseline PINP, CTX and BMDwith end-of-trial measures aiming
to unravel potential beneficial effects of exenatide on BTMs and
BMDs.
METHODS
Details of the “TAO study” have previously been reported (17–
20). Below, key methodology, experimental procedures and
analyses are outlined.
Study Population and Procedures
Inclusion criteria included clinically stable schizophrenia
spectrum patients (ICD-10 diagnoses F20.x and F25.x);
treatment with minimum one antipsychotic drug; age 18
to 65 years; obesity (BMI ≥ 30 kg/m2). Exclusion criteria
included substance dependence, diabetes (any type), severe
somatic disease, pregnancy and breastfeeding. Patients were
randomized to either receive injections of 2mg exenatide
once-weekly (Bydureon R©, AstraZeneca AB, Södertälje, Sweden)
or placebo. We used the solvent from the Bydureon R© kit as
placebo. Unblinded trial staff otherwise not involved in the
study performed the subcutaneous injections of exenatide or
placebo ensuring 100% medication adherence. Both groups were
assessed with biochemical analyses and DXA measurements at
trial initiation and after 3 months (12–16 weeks) (17).
Biochemical Analyses
All biochemical analyses were performed at the Department
of Clinical Biochemistry, Rigshospitalet, Copenhagen, Denmark.
Since CTX (8) and prolactin (22) are influenced by diurnal
variations, all blood samples were collected in themorning before
food intake (fasting>8 h).
Bone Mineral Density
Patients underwent DXA examinations on a Lunar Prodigy
whole-body scanner (GE Medical Systems, Madison, Wisconsin,
USA). As input for statistical analyses, we calculated averages
of the left and right femoral neck measurements and the left
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and right total femur measurements. T-score and Z-score were
not calculated for patients below 20 years of age. Likewise,
we calculated standardized BMD values from the raw data as
described by Fan et al. (23).
Statistical Analyses
To enable comparison with the sex and age intervals obtained
from the background population cohort (21), we split patients
into men and women and compared baseline levels of PINP,
CTX, and BMD for each group and age interval, separately.
Baseline demographic and clinical variables were tested with
independent t-tests for continuous data, and χ2-test for nominal
data. Non-normally distributed BTM and BMD values were
transformed by logarithm or square root to achieve normal
distribution. All outcomes were initially analyzed without
covariates by two-way repeated measures ANOVA. Next,
analyses were repeated with mean prolactin level [(baseline +
follow-up)/2] as a covariate to evaluate the potential effect of
prolactin. We a priori decided to repeat analyses after excluding
patients with baseline values, which could indicate pre-study
disturbance of bone metabolism (vitamin D< 30 nmol/L and/or
parathyroid hormone (PTH) >7.63 pmol/L) (24). IBM SPSS
Statistics Version 22 (IBMCorp. forWindows, Armonk, NY) was
used for statistical analyses. The significance level was set to 0.05,
and all tests were two-tailed.
RESULTS
Demographic and Clinical Data
In total, 45 patients were included in the baseline analyses.
Twenty patients in the exenatide-treated group and 20
patients in the placebo-treated group completed the trial
(Supplementary Figure 1). At baseline we found no significant
group differences in age, sex, ethnicity, illness duration,
education, body weight, BMI, diagnosis or antipsychotic
medication. However, we found a higher proportion
(p = 0.02) of current smokers in the exenatide group
(Supplementary Table 1). After 3 months of exenatide or
placebo treatment patients lost 2.3 kg with no significant
difference between groups (18, 20).
Comparison of Baseline Bone Turnover
Markers to Reference Values
PINP and CTX concentrations were within the age-adjusted
reference range (21) for all women (24 of 24). One of 21 male
patients (5%) had lower PINP, and three male patients (14%) had
lower CTX levels than the corresponding age-adjusted reference
range (Figure 1A).
Comparison of Baseline Bone Mineral
Density to Reference Values
One hundred and fourteen (86%) out of the total 132 DXA
measurements corresponded to Z-scores between ±2. One
patient had a Z-score (L2–L4) < −2. In both the L2–L4 and
the total femur measurements five patients (11%) had Z-scores
above 2, whereas in the femoral neck BMD measurement four
patients (9%) had Z-scores above 2 (Figure 1B). Ten patients
(23%), [4 women (17%), and 6 men (29%)] had T-scores < −1
indicating osteopenia. No patients had osteoporosis (T-scores
≤−2.5) (Figure 1B).
Effect of Exenatide on Biomarkers of Bone
Turnover and Bone Mineral Density
After 3 months we observed numerical reductions in levels of
both PINP and CTX in the exenatide-treated group, whereas the
levels in the placebo-treated group numerically increased. For
PINP, we found a time × group interaction (i.e., a treatment
effect) at trend-level significance (p = 0.05), however, when
prolactin was included as a covariate this trend-level observation
was no longer present. For CTX, we observed no significant
interactions. Apart from a trend-level increase in osteocalcin over
time in both groups, analyses on other bone-related biomarkers
were non-significant (Table 1).
Analyses of BMD data (Table 1) revealed a significant time ×
group interaction (p = 0.016) in the L2–L4, indicating higher
BMD after exenatide treatment and lower BMD after placebo.
After correction for the mean prolactin level, this interaction
was only significant at trend-level (p = 0.057). The remaining
analyses of BMD were not significant.
Exclusion of four patients with suspected pre-study
disturbance of bone metabolism did not change the significance
levels of the above results.
DISCUSSION
The current analyses of bone status in chronic, obese, non-
diabetic, antipsychotic-treated schizophrenia spectrum patients
indicated that most patients had BTMs, i.e., PINP and CTX levels
within the reference ranges obtained from a Danish background
population (21). On the contrary, our BMD measurements
indicated that 23% of patients had osteopenia. However, in men
younger than 50 years of age and premenopausal women, T-
scores are typically not used for BMD (25), rather Z-scores are
preferred. Nevertheless, a meta-analysis of prevalence of low
bone mass in schizophrenia patients reported an even higher
prevalence of osteopenia which was present in both patients
and controls (around 40%) (26). This could be explained by the
fact that the patients included in our trial were markedly obese
(mean BMI 38.8 kg/m2), and obesity is generally associated with
increased BMD. Paradoxically, obesity has also been associated
with an increase in fracture risk (27). Hence, the seemingly
unaffected BMD observed in our patient sample may still render
the patients at an increased risk of fractures, but the association
between BMI and fracture risk is complex (28), and fracture risk
was beyond what could be assessed from the current data.
The mean age of our patients was 35.8 years, and with one
exception, all sex and age-adjusted BMD Z-score measurements
were within the normal range. In fact, five patients (12%) had
Z-scores above 2 in L2–L4 and total femur measurements,
and four patients (9%) had Z-scores above 2 in the femoral
neck BMD measurement (Figure 1B). Therefore, in contrast to
our expectations, the current comparative baseline analyses do
not lend overall support to the emerging concern of markedly
compromised bone status in chronic schizophrenia patients. As
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FIGURE 1 | Comparison of bone turnover markers and bone mineral density in the study cohort with the background population. (A) Procollagen type I N-terminal
propeptide (PINP) and C-terminal cross-linking telopeptide of type I collagen (CTX) levels in the study cohort with reference ranges obtained from the background
population (21). Geometric means for the reference intervals are plotted. (B) Bone mineral density values of the lumbar spine L2–L4, left and right femoral neck, as well
as left and right total femur (acquired using CORE software [version 14.1]). Age is plotted against Z-scores (average values for a healthy population of the same age
and same sex) (left panel) and T-scores (average values for young healthy subjects of the same sex) (right panel). In the plot of Z-scores, ±2 standard deviations are
presented. In the plot of T-scores, the cutoffs for osteopenia and osteoporosis are presented (T-score = −1 SD and T-score = −2.5 SD).
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TABLE 1 | Effect of exenatide and placebo on biomarkers related to bone metabolism and on bone mineral density.
Blood marker Exenatide
(n = 20)
Mean ± SD [Range]
Placebo
(n = 20)
Mean ± SD [Range]
Time
p-value
Group
p-value
Time x Group
p-value
(No covariance)
Time x Group
p-value
(Prolactin
covariance)
C-terminal cross-linking telopeptide of type I
collagen (ng/L) $
Baseline 409.0 ± 229.6
[170–1160]
475.5 ± 265.7
[30-950]
0.93 0.19 0.15 0.25
End of trial 357.0 ± 171.9
[80–780]
514.5 ± 292.5
[60–1420]
Procollagen type I N-terminal propeptide
(µg/L)
Baseline 49.3 ± 23.0
[18.5–128.4]
52.4 ± 24.9
[2.0-97.7]
0.52 0.27 0.05 0.39
End of trial 46.1 ± 20.5
[17.2–104.3]
58.7 ± 24.4
[29.2–111.9]
Bone-specific alkaline phosphatase (µg/L)
Baseline 20.9 ± 8.3
[11.3–47.1]
22.2 ± 10.3
[8.2–50.8]
0.65 0.55 0.61 0.26
End of trial 20.8 ± 7.3
[11.3–37.5]
22.8 ± 9.7
[8.7–48.6]
Osteocalcin (µg/L) §
Baseline
End of trial
14.3 ± 7.6
[2.0–37.7]
15.4 ± 5.9
[8.0–33.5]
16.1 ± 8.0
[6.2–39.0]
17.8 ± 8.5
[8.7–42.4]
0.05 0.28 0.71 0.40
Osteocalcin/CTX ratio §
Baseline
End of trial
40.3 ± 21.1
[4.3–96.5]
54.1 ± 39.2
[18.7–176.7]
51.5 ± 52.4
[19.2–256.7]
47.0 ± 40.7
[14.6–188.3]
0.28 0.86 0.11 0.24
Parathyroid hormone (pmol/L) $
Baseline
End of trial
4.30 ± 3.30
[1.0–14.7]
3.71 ± 1.88
[1.1–9.6]#
4.15 ± 1.90
[1.1–10.8]#
4.08 ± 1.81
[1.5–9.3]#
0.32 0.75 0.30 0.31
Prolactin (mIU/L) §
Baseline
End of trial
369.6 ± 397.3
[24.1–1484.0]
357.7 ± 404.0
[20.9–1416.0]
435.3 ± 434.9
[34.2–1614.0]
372.8 ± 393.7
[30.4–1502.0]
0.11 0.74 0.42
–
Vitamin D (nmol/L)
Baseline
End of trial
62.9 ± 33.8
[8.0–126.0]
69.0 ± 37.7
[16.2–135.0]
70.4 ± 33.6
[14.2–130.0]
72.8 ± 31.3
[17.0–136.0]
0.14 0.59 0.51 0.67
Dual-energy X-ray
absorptiometry—Bone mineral density
(g/cm2)
Exenatide
(n = 20)
Mean ± SD [Range]
Placebo
(n = 19)
Mean ± SD [Range]
Time
p-value
Group
p-value
Time x Group
p-value
(No covariance)
Time x Group
p-value
(Prolactin
covariance)
L2–L4
Baseline
End of trial
1.23 ± 0.19
[0.90–1.68]
1.24 ± 0.19
[0.93–1.67]
1.13 ± 0.16
[0.92–1.49]
1.12 ± 0.16
[0.88–1.48]
0.576 0.055 0.016* 0.057
Femoral neck
Baseline
End of trial
1.05 ± 0.13
[0.82–1.28]
1.04 ± 0.13
[0.76–1.26]
1.00 ± 0.10
[0.80–1.21]
1.00 ± 0.10
[0.82–1.16]
0.125 0.223 0.576 0.720
Total femur
Baseline
End of trial
1.12 ± 0.12
[0.90–1.38]
1.13 ± 0.11
[0.89–1.40]
1.08 ± 0.11
[0.90–1.35]
1.08 ± 0.11
[0.90–1.35]
0.976 0.212 0.419 0.070
Bone mineral density was measured with dual-energy X-ray absorptiometry scanning. All outcomes were initially analyzed without covariates by two-way repeated measures ANOVA,
where the between-subject factor, i.e. exenatide vs placebo, was denoted “Group,” and the within-subject factor between time points was denoted “Time.” A significant “Time × Group
interaction” would indicate a difference in response between the two treatment groups. Results from ANOVA/ANCOVA are corrected for age and sex. P-values are rounded to two
decimals and significant p-values are shown with an asterisk (*). The table is based on data from patients, who completed the trial.
# One observation missing. $ Square root-transformed to obtain normal distribution. § Natural logarithm-transformed to obtain normal distribution. Alkaline phosphatase and parathyroid
hormone (PTH) were measured on the Vitros 5.1FS or the Vitros 5600 chemistry analyzer (Ortho Clinical Diagnostics, Raritan, NJ, USA) and total 25-hydroxycholecalciferol (vitamin D)
was measured on the Cobas e411 analyzer (Roche Diagnostics, Rotkreuz, Switzerland). All three assays are electro-chemiluminescence binding assays. Prolactin was measured using
an immunofluorimetric assay on the BRAHMS Kryptor Compact Plus analyzer (Thermo Scientific, Hennigsdorf, Germany). Plasma PINP, plasma CTX, plasma osteocalcin, and serum
bone-specific alkaline phosphatase were measured with chemiluminescence immunoassays using the automated analyzer, iSYS (Immunodiagnostic Systems plc, Tyne and Wear, UK)
according to the manufacturer’s instructions.
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noted above the presence of marked obesity may partly explain
these findings.
We observed that treatment with exenatide resulted in a
trend-level reduction in PINP, and a significant increase in the
BMD measurement of L2–L4. The reduction in PINP in the
exenatide-treated group contrasts a previously reported increase
of PINP in obese women, who experienced a 12% body weight
reduction after 12 months of liraglutide treatment (14). In our
3 months study, patients experienced a weight loss of 2.3 kg
corresponding to a subtle reduction in body weight of around
2%. Based on these placebo-controlled studies it could appear
that GLP-1 receptor agonists may affect PINP, however, the
directionality of this change may be influenced by antipsychotic
exposure or by concurrent changes in body weight. Additionally,
the two GLP-1 receptor agonists liraglutide and exenatide may
also affect levels of PINP differently.
Finally, in our study the potential effect of exenatide on bone
markers did not remain significant after correction for mean
prolactin levels. The limited sample size and large variability
in prolactin level render the impact of this finding unclear.
Although a previous study did not find correlation between
prolactin levels and BMD measures (5), modulation of the
dopamine system by GLP-1 receptor agonism has previously
been suggested (29). Nevertheless, our current observation of a
potential interplay between prolactin levels and effect of GLP-1
receptor agonists, suggests that correction for prolactin in future
studies of antipsychotic-treated patients should be considered.
The current study has some limitations. The 3 months
study period, and the relatively young (with respect to bone
status), and non-diabetic sample compromise the inferences
which can be drawn from the present data. Firstly, our
patients and the population cohort were not matched on BMI
(30). Moreover, we intentionally included a naturalistic trial
population (18), which is reflected in the broad medication
profiles (Supplementary Table 1). To this end, individual
antipsychotic compounds may affect prolactin levels (22, 31, 32),
and bone status differentially, but the current data did not allow
for separating effects of specific antipsychotics. Finally, patients
were not instructed to keep their level of physical activity stable
and refrain from taking vitamin D supplements during the trial,
and we were therefore unable to control for these potential
confounders.
In conclusion, these planned secondary analyses of the TAO
study showed that sex and age-adjusted measures of bone status
were comparable to the Danish reference population. Subtle
changes in bone markers over a 3 months treatment course
with the GLP-1 receptor agonist exenatide may suggest beneficial
effects of GLP-1 on bone status in antipsychotic-treated, obese
patients, whichmay relate to GLP-1-induced changes in prolactin
levels.
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